Finerenone and empagliflozin for obesity with high blood pressure
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial tests whether combining two medicines (finerenone and empagliflozin) can help people who are overweight or have obesity and have high blood pressure that is not well controlled. It aims to see if the combination works better than placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older.
- You have obesity (a BMI of 28 or higher) or extra belly fat (waist size 90 cm or more for men, 85 cm or more for women, or other measures of abdominal obesity).
- Your systolic blood pressure (top number) is between 140 and 160 mmHg when measured without a doctor present.
- You take no more than 2 blood pressure medicines, and the dose has not changed in the last 4 weeks.
- You do not have diabetes, heart failure, or serious kidney or liver problems.
- You are not taking certain other medicines for weight loss or heart/kidney conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new treatment combination (finerenone plus a water pill) works better than a standard fixed-dose combination for people with both high blood pressure and chronic kidney disease. It aims to find which option provides more clinical benefit.
This trial tests if a medicine (SGLT2 inhibitor) given to people with high blood pressure and early signs of heart stress can help prevent heart failure. You may join if your blood pressure is controlled but tests show your heart is beginning to struggle.
This study tests if the diabetes drug empagliflozin can help people with pulmonary arterial hypertension (PAH), a condition causing high blood pressure in the lungs. It aims to see if the drug improves symptoms and is safe for patients with moderate symptoms.
This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.
This trial tests whether adding two heart medicines together (finerenone and an SGLT2 inhibitor) helps people who are in the hospital for heart failure recover better. It may be an option for you if you are currently hospitalized and your heart stress markers are high.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
Hear when a new Hypertension (HTN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.